Increased density of I2-imidazoline receptors in human glioblastomas

NeuroReport

Volumn 7, Issue 8, 1996, Pages 1393-1396

  Martín Gómez, J Ignacio ^a   Ruiz, Javier ^a   Callado, Luis F ^a   Garibi, Jesús M ^b   Aguinaco, Luis ^c   Barturen, Fernando ^a   Meana, J Javier ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c Hospital Santiago   (Spain)

Author keywords

Astrocytoma; Brain tumour; Glia; Glioblastoma multiforme; Glioma; I2 imidazoline receptor; Idazoxan; Idazoxan binding sites; Meningioma; Neuroreceptors

Indexed keywords

IDAZOXAN; IMIDAZOLINE RECEPTOR; DRUG RECEPTOR; IMIDAZOLINE RECEPTORS;

ADULT; ARTICLE; ASTROCYTOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; PRIORITY JOURNAL; RECEPTOR BINDING; AGED; BRAIN TUMOR; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; POSTOPERATIVE PERIOD; RADIOASSAY; STATISTICAL MODEL;

AGED; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; IDAZOXAN; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RADIOLIGAND ASSAY; RECEPTORS, DRUG;

EID: 0029658021     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199605310-00013     Document Type: Article

References (25)

1. Bousquet P, Feldman J, Bloch R et al. J Pharmacol Exp Ther 230, 232-236 (1984).
2. Miralles A, Olmos G, Sastre M et al. J Pharmacol Exp Ther 264, 1187-1197 (1993).
3. Mallard NJ, Hudson AL and Nutt DJ. Br J Pharmacol 106, 1019-1027 (1992).
4. Ernsberger P, Damon TH, Graff LM et al. J Pharmacol Exp Ther 264, 172-182 (1993).
5. Regunathan S, Feinstein DL and Reis DJ. J Neurosci Res 34, 681-688 (1993).
6. Olmos G, Alemany R, Escriba PV et al. Br J Pharmacol 111, 997-1002 (1994).
7. Alemany R, Olmos G and Garcia-Sevilla JA. Br J Pharmacol 114, 837-845 (1995).
8. Russell DS and Rubinstein LJ. Pathology of Tumours of the Nervous System. 5th edn. London: Edward Arnold, 1989: 93.
9. Earnest P, Kelly PJ, Scheithauer BW et al. Radiology 166, 823-827 (1988).
10. Olivero WC, Dulebohn SC and Lister JR. J Neurol Neurosurg Psychiatry 58, 250-252 (1995).
11. Kleihues P, Burger PC and Scheithauer BW. Brain Pathol 3, 255-268 (1993).
12. Ruiz J, Martin I, Callado LF et al. Neurosci Lett 160, 109-112 (1993).
13. Munson PJ and Rodbard D. Anal Biochem 107, 220-239 (1980).
14. De Lean A, Munson PJ and Rodbard D. Am J Physiol 235, E97-E102 (1978).
15. Ernsberger PR, Westbrooks KL, Christen MO et al. J Cardiovasc Pharmacol 20 (Suppl 4): S1-S10 (1992).
16. Hudson AL, Husbands S, Lewis JW et al. Br J Pharmacol 112, 320P (1994).
17. Sastre M and Garcia-Sevilla JA. J Neurochem 61, 881-889 (1993).
18. O'Callaghan JP and Miller DB. Neurobiol Aging 12, 171-174 (1991).
19. Duffy PE, Rapport M and Graf L. Neurology 30, 778-782 (1980).
20. Takada A, Mitsuka S, Diksic M et al. Eur J Pharmacol (Environ Toxicol Pharmacol Sec) 228, 131-139 (1992).
21. Olson JMM, Junck L, Young AB et al. Cancer Res 48, 5837-5841 (1988).
22. Black KL, Ikezaki K, Santoti E et al. Cancer 65, 93-97 (1990).
23. Renouatd A, Widdowson PS and Cordi A. Br J Pharmacol 109, 625-631 (1993).
24. Tesson P, Prip-Buus C, Lemoine A et al. J Biol Chem 266, 155-160 (1991).
25. Tesson P, Limon-Boulez I, Urban P et al. J Biol Chem 270, 9856-9861 (1995).